Form 4: 2seventy bio, Inc. Completes Merger with Bristol-Myers Squibb Subsidiary

Casdin Capital, LLC reports the tendering of shares and conversion of stock options and restricted stock units following the merger of 2seventy bio, Inc. with a subsidiary of Bristol-Myers Squibb Company.

Summary

• This Form 4 filing details the changes in beneficial ownership for Casdin Capital, LLC, Eli Casdin, Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC following the merger of 2seventy bio, Inc. with Daybreak Merger Sub Inc., a subsidiary of Bristol-Myers Squibb Company.
• The merger consideration was $5.00 per share.
• Shares held by the reporting persons were tendered as part of the merger agreement.
• Restricted stock units (RSUs) were fully vested, cancelled, and converted into the right to receive $5.00 per share.
• Stock options with an exercise price less than $5.00 were fully vested, cancelled, and converted into the right to receive the difference between $5.00 and the exercise price.
• Eli Casdin ceased to be a member of the Company's board of directors as a result of the merger.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The merger provides a clear exit strategy for shareholders at a defined price. The completion of the merger removes uncertainty for investors.

Positives

• The merger provided a cash payout of $5.00 per share for shareholders.
• All outstanding stock options with an exercise price below the merger consideration were converted to cash, providing value to option holders.
• Restricted stock units were fully vested and converted to cash.

Negatives

• Eli Casdin ceased to be a member of the Company's board of directors.

Future Outlook

The company will continue as the surviving corporation and a wholly-owned subsidiary of Bristol-Myers Squibb Company.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This merger reflects ongoing consolidation in the biotechnology industry, where larger pharmaceutical companies acquire smaller firms with promising technologies or drug candidates.

Comparison to Industry Standards

• Mergers in the biotech industry often involve a premium paid over the existing share price to incentivize shareholders to approve the deal.
• The $5.00 per share merger consideration would need to be compared to 2seventy bio's trading price prior to the announcement to assess the premium offered.
• Comparable transactions in the cell and gene therapy space, such as Gilead's acquisition of Kite Pharma, can provide benchmarks for valuation multiples and deal structures.

Management Changes

Stakeholder Impact

• Shareholders received $5.00 per share in cash.
• Employees of 2seventy bio, Inc. now work for a subsidiary of Bristol-Myers Squibb Company.
• The merger may impact the company's relationships with its suppliers and customers.

Key Dates

Keywords

Merger, 2seventy bio, Bristol-Myers Squibb, Casdin Capital, Form 4, Beneficial Ownership, Tender Offer, Stock Options, Restricted Stock Units